Head-to-head evidence
Carfilzomib vs TQB3602
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: October 2026 · NCT06140966 (registry estimate)
TQB3602
Developed by Sino Biopharmaceutical
NCT04275583 · Phase 1 · status unknown
This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · TQB3602's landscape